• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4597351)   Today's Articles (5544)   Subscriber (49348)
For: Ruof J, Knoerzer D, Dünne AA, Dintsios CM, Staab T, Schwartz FW. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany. Health Policy 2014;118:242-54. [PMID: 25194474 DOI: 10.1016/j.healthpol.2014.08.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 07/30/2014] [Accepted: 08/15/2014] [Indexed: 11/28/2022]
Number Cited by Other Article(s)
1
Szamreta EA, Monberg MJ, Desai KD, Li Y, Othus M. Prognosis and conditional survival among women with newly diagnosed ovarian cancer. Gynecol Oncol 2024;180:170-177. [PMID: 38211405 DOI: 10.1016/j.ygyno.2023.11.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 10/31/2023] [Accepted: 11/16/2023] [Indexed: 01/13/2024]
2
Julian E, Pavlovic M, Sola-Morales O, Gianfrate F, Toumi M, Bucher HC, Dierks C, Greiner W, Mol P, Bergmann JF, Salmonson T, Hebborn A, Grande M, Cardone A, Ruof J. Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy. HEALTH ECONOMICS REVIEW 2022;12:54. [PMID: 36333433 PMCID: PMC9636785 DOI: 10.1186/s13561-022-00402-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 10/18/2022] [Indexed: 06/08/2023]
3
Lux MP, Ciani O, Dunlop WCN, Ferris A, Friedlander M. The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This? Cancer Manag Res 2021;13:8457-8471. [PMID: 34795526 PMCID: PMC8592394 DOI: 10.2147/cmar.s328058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 09/27/2021] [Indexed: 11/23/2022]  Open
4
Ciani O, Grigore B, Blommestein H, de Groot S, Möllenkamp M, Rabbe S, Daubner-Bendes R, Taylor RS. Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. Med Decis Making 2021;41:439-452. [PMID: 33719711 PMCID: PMC8108112 DOI: 10.1177/0272989x21994553] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 01/21/2021] [Indexed: 12/03/2022]
5
Grigore B, Ciani O, Dams F, Federici C, de Groot S, Möllenkamp M, Rabbe S, Shatrov K, Zemplenyi A, Taylor RS. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. PHARMACOECONOMICS 2020;38:1055-1070. [PMID: 32572825 DOI: 10.1007/s40273-020-00935-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
6
Bauer A, Wittenberg R, Ly A, Gustavsson A, Bexelius C, Tochel C, Knapp M, Nelson M, Sudlow C. Valuing Alzheimer's disease drugs: a health technology assessment perspective on outcomes. Int J Technol Assess Health Care 2020;36:1-7. [PMID: 32847642 DOI: 10.1017/s0266462320000574] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
7
Dintsios CM, Beinhauer I. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany. HEALTH ECONOMICS REVIEW 2020;10:7. [PMID: 32172494 PMCID: PMC7071579 DOI: 10.1186/s13561-020-00263-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2019] [Accepted: 02/28/2020] [Indexed: 05/03/2023]
8
Stahel RA, Lacombe D, Cardoso F, Casali PG, Negrouk A, Marais R, Hiltbrunner A, Vyas M. Current models, challenges and best practices for work conducted between European academic cooperative groups and industry. ESMO Open 2020;5:e000628. [PMID: 32213534 PMCID: PMC7103800 DOI: 10.1136/esmoopen-2019-000628] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 01/15/2020] [Accepted: 01/20/2020] [Indexed: 12/03/2022]  Open
9
Molitor M, Dintsios CM. Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA. Expert Rev Pharmacoecon Outcomes Res 2020;21:145-157. [DOI: 10.1080/14737167.2020.1729131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
10
Isbary G, Staab TR, Amelung VE, Dintsios CM, Iking-Konert C, Nesurini SM, Walter M, Ruof J. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2018;21:698-706. [PMID: 29909875 DOI: 10.1016/j.jval.2017.09.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 09/17/2017] [Indexed: 06/08/2023]
11
Niehaus I, Dintsios CM. Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. Health Policy 2018;122:599-606. [PMID: 29605527 DOI: 10.1016/j.healthpol.2018.03.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 03/17/2018] [Accepted: 03/19/2018] [Indexed: 10/17/2022]
12
Theidel U, von der Schulenburg JMG. Benefit assessment in Germany: implications for price discounts. HEALTH ECONOMICS REVIEW 2016;6:33. [PMID: 27485438 PMCID: PMC4970987 DOI: 10.1186/s13561-016-0109-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 07/22/2016] [Indexed: 05/20/2023]
13
Ruof J, Staab T, Dintsios CM, Schröter J, Schwartz FW. Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified? HEALTH ECONOMICS REVIEW 2016;6:46. [PMID: 27687714 PMCID: PMC5042914 DOI: 10.1186/s13561-016-0124-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2016] [Accepted: 09/16/2016] [Indexed: 05/31/2023]
14
Ruof J, Staab T, Dintsios CM, Schröter J, Schwartz FW. Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified? HEALTH ECONOMICS REVIEW 2016. [PMID: 27687714 DOI: 10.11186/s13561-016-0124-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
15
Staab T, Isbary G, Amelung VE, Ruof J. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases. BMC Health Serv Res 2016;16:651. [PMID: 27842592 PMCID: PMC5109700 DOI: 10.1186/s12913-016-1902-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 11/04/2016] [Indexed: 11/10/2022]  Open
16
Ruof J, Flückiger O, Andre N. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients? Drugs R D 2015;15:221-6. [PMID: 26286202 PMCID: PMC4561053 DOI: 10.1007/s40268-015-0100-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
17
Bullinger M, Blome C, Sommer R, Lohrberg D, Augustin M. Gesundheitsbezogene Lebensqualität – ein zentraler patientenrelevanter Endpunkt in der Nutzenbewertung medizinischer Maßnahmen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2015;58:283-90. [DOI: 10.1007/s00103-014-2107-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
18
Kaiser T, Vervölgyi V, Wieseler B. [Benefit assessment of drugs]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2015;58:232-9. [PMID: 25566842 DOI: 10.1007/s00103-014-2110-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA